regn

The quick read

What's driving the attention

Regeneron Pharmaceuticals (REGN) is under scrutiny after analysts lowered its price targets despite significant company news.

The Regeneron Pharmaceuticals trend is driven by investor and market interest following recent analyst price target reductions and the company's engagement with drug pricing pledges, including being the last major drugmaker to sign President Trump's drug pricing initiative. Despite these factors, several financial sources report varying outlooks with some rating the stock as hold and adjusting target prices downward.